New Deal : Merck licenses experimental psoriasis drug to India's Sun Pharma

Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million. Under the agreement, Sun Pharma will acquire the worldwide rights to the drug, tildrakizumab, for all possible indications. The drug is currently in late-stage trials for use in chronic plaque psoriasis, an inflammatory skin disease. 

Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including manufacturing and marketing the approved product, the companies said. Merck's shares were down about 1 percent at $59.41 on the New York Stock Exchange on Wednesday. Sun Pharmaceutical's shares closed at 792.40 rupees on the National Stock Exchange of India.

P.S. : Contact Turacoz Healthcare Solutions for any requirement in medical communication for pharmaceutical and biotech companies. Turacoz team is comprised of qualified medical writers with an experience ranging from 3 years to 30 years. The team is well equipped to take on projects of regulatory writing, scientific publications and medico-marketing related documents. They have thorough knowledge and understanding of ICH guidelines in different geographical regions, medical writing guidelines by ICMJE (International Committee of Medical Journal Editors), and region wise/client specific assignments.